These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 843395)

  • 1. Production in vivo of falloff monosomes in mouse liver by sparsomycin.
    Hayes LC; Plapp FV; Tilzer LL; Reddy JK; Chiga M
    Biochem Pharmacol; 1977 Feb; 26(3):255-6. PubMed ID: 843395
    [No Abstract]   [Full Text] [Related]  

  • 2. Sparsomycin-induced disaggregation but not detachment of hepatic membrane-bound polyribosomes.
    Sidransky H; Verney E; Murty CN; Sarma DS
    Proc Soc Exp Biol Med; 1978 Apr; 157(4):660-4. PubMed ID: 652806
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of sparsomycin in vivo and in vitro on hepatic polyribosomes and protein synthesis.
    Sarma DS; Murty CN; Sidransky H
    Biochem Pharmacol; 1974 Feb; 23(4):857-65. PubMed ID: 4824509
    [No Abstract]   [Full Text] [Related]  

  • 4. Necessity of the sulfoxide moiety for the biochemical and biological properties of an analog of sparsomycin.
    Flynn GA; Ash RJ
    Biochem Biophys Res Commun; 1983 Jul; 114(1):1-7. PubMed ID: 6349625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different susceptibility of protein synthesis to inhibitors of elongation in cell-free systems from plasma cell tumours and reticulocytes.
    Emmerich B; Hoffman H; Erben V; Rastetter J
    Biochim Biophys Acta; 1976 Nov; 447(4):460-73. PubMed ID: 974138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Trypanosoma brucei brucei peptidyl transferase activity by sparsomycin analogs and effects on trypanosome protein synthesis and proliferation.
    Bitonti AJ; Kelly SE; Flynn GA; McCann PP
    Biochem Pharmacol; 1985 Sep; 34(17):3055-60. PubMed ID: 4038323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cross-resistance of mouse blasticidin S-resistant cell lines to puromycin and sparsomycin, inhibitors of ribosome function.
    Kuwano M; Takenaka K; Ono M
    Biochim Biophys Acta; 1979 Jul; 563(2):479-89. PubMed ID: 465501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of protein biosynthesis: the first active sparsomycin analog.
    Vince R; Brownell J; Lee CK
    Biochem Biophys Res Commun; 1977 Apr; 75(3):563-7. PubMed ID: 856177
    [No Abstract]   [Full Text] [Related]  

  • 9. In vivo rates of deaggregation of polyribosomes in normal and regenerating liver after the injection of pactamycin.
    Scornik OA
    Biochim Biophys Acta; 1974 Nov; 374(1):76-81. PubMed ID: 4429742
    [No Abstract]   [Full Text] [Related]  

  • 10. Transfer RNA content and dissociability of mouse liver monosomes produced by histidinol.
    Hayes LC; Plapp FV; Tilzer LL; Chiga M
    Biochem Biophys Res Commun; 1975 Jul; 65(1):258-64. PubMed ID: 1147987
    [No Abstract]   [Full Text] [Related]  

  • 11. Certain characteristics of monosomes produced by carbon tetrachloride.
    Tilzer LL; Plapp FV; Hayes LC; Chiga M
    Biochem Pharmacol; 1975 Jan; 24(1):99-101. PubMed ID: 1122265
    [No Abstract]   [Full Text] [Related]  

  • 12. Characterization of monosomes produced by aflatoxin B1.
    Hayes LC; Plapp FV; Tilzer LL; Chiga M
    Chem Biol Interact; 1975 May; 10(5):343-7. PubMed ID: 1139735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and activity of pyrimidinylpropenamide antibiotics: the alkyl analogues of sparsomycin.
    Nakajima N; Enomoto T; Watanabe T; Matsuura N; Ubukata M
    Biosci Biotechnol Biochem; 2003 Dec; 67(12):2556-66. PubMed ID: 14730133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical and biological aspects of sparsomycin, an antibiotic from Streptomyces.
    Ottenheijm HC; van den Broek LA; Ballesta JP; Zylicz Z
    Prog Med Chem; 1986; 23():219-68. PubMed ID: 3310108
    [No Abstract]   [Full Text] [Related]  

  • 15. Sparsomycin analogs. IV. Synthesis and antitumor activity of pyrimidine-5-carboxamides and (E)-beta-(pyrimidin-5-yl)acrylamides.
    Kanatomo S; Wada A; Yomei M; Hase T; Nagai S; Fukuda S; Tanaka M; Sasaki T
    Chem Pharm Bull (Tokyo); 1988 Jun; 36(6):2042-9. PubMed ID: 3240439
    [No Abstract]   [Full Text] [Related]  

  • 16. The development of sparsomycin as an anti-tumour drug.
    Ottenheijm HC; van den Broek LA
    Anticancer Drug Des; 1988 Mar; 2(4):333-7. PubMed ID: 3365303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute effects of selected hepatotoxic agents on polyribosomes and protein synthesis in the livers of rats fed purified diets containing hepatocarcinogens.
    Sidransky H; Verney E
    Exp Mol Pathol; 1982 Feb; 36(1):72-85. PubMed ID: 7056372
    [No Abstract]   [Full Text] [Related]  

  • 18. Importance of the hydrophobic sulfoxide substituent on nontoxic analogs of sparsomycin.
    Ash RJ; Fite LD; Beight DW; Flynn GA
    Antimicrob Agents Chemother; 1984 Apr; 25(4):443-5. PubMed ID: 6375553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulfoxide configuration in sparsomycin determines time-dependent and competitive inhibition of peptidyl transferase.
    Ash RJ; Flynn GA; Liskamp RM; Ottenheijm HC
    Biochem Biophys Res Commun; 1984 Dec; 125(2):784-9. PubMed ID: 6393983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sparsomycin analogs. VI. Synthesis and antitumor activity of octylsparsomycin analogs.
    Kanatomo S; Hase T; Wada A; Ohki K; Nagai S; Tanaka M; Sasaki T
    Chem Pharm Bull (Tokyo); 1989 Mar; 37(3):688-91. PubMed ID: 2752478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.